Re: a large pooled analysis of benefit of herceptin beyond progression in Stage IVs
The problem is that CSF has a high turnover and that the concentration seen in my Xeloda/Tykerb treated patient CSF was still less than 10% of the blood concentration. High concentrations were found to be needed in the CSF to be effective. This was also true with three other patients that are seeing some success with IT Herceptin.
|